Your browser doesn't support javascript.
loading
Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial.
Reyman, Marta; van Houten, Marlies A; Watson, Rebecca L; Chu, Mei Ling J N; Arp, Kayleigh; de Waal, Wouter J; Schiering, Irene; Plötz, Frans B; Willems, Rob J L; van Schaik, Willem; Sanders, Elisabeth A M; Bogaert, Debby.
Afiliação
  • Reyman M; Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital and University Medical Center Utrecht, Utrecht, the Netherlands.
  • van Houten MA; Department of Pediatrics, Spaarne Gasthuis, Hoofddorp and Haarlem, the Netherlands.
  • Watson RL; Department of Pediatrics, Spaarne Gasthuis, Hoofddorp and Haarlem, the Netherlands.
  • Chu MLJN; Medical Research Council and University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
  • Arp K; Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital and University Medical Center Utrecht, Utrecht, the Netherlands.
  • de Waal WJ; Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital and University Medical Center Utrecht, Utrecht, the Netherlands.
  • Schiering I; Department of Pediatrics, Diakonessenhuis, Utrecht, the Netherlands.
  • Plötz FB; Department of Pediatrics, Spaarne Gasthuis, Hoofddorp and Haarlem, the Netherlands.
  • Willems RJL; Department of Pediatrics, Tergooiziekenhuis, Blaricum, the Netherlands.
  • van Schaik W; Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • Sanders EAM; Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
  • Bogaert D; Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital and University Medical Center Utrecht, Utrecht, the Netherlands.
Nat Commun ; 13(1): 893, 2022 02 16.
Article em En | MEDLINE | ID: mdl-35173154
ABSTRACT
Broad-spectrum antibiotics for suspected early-onset neonatal sepsis (sEONS) may have pronounced effects on gut microbiome development and selection of antimicrobial resistance when administered in the first week of life, during the assembly phase of the neonatal microbiome. Here, 147 infants born at ≥36 weeks of gestational age, requiring broad-spectrum antibiotics for treatment of sEONS in their first week of life were randomized 111 to receive three commonly prescribed intravenous antibiotic combinations, namely penicillin + gentamicin, co-amoxiclav + gentamicin or amoxicillin + cefotaxime (ZEBRA study, Trial Register NL4882). Average antibiotic treatment duration was 48 hours. A subset of 80 non-antibiotic treated infants from a healthy birth cohort served as controls (MUIS study, Trial Register NL3821). Rectal swabs and/or faeces were collected before and immediately after treatment, and at 1, 4 and 12 months of life. Microbiota were characterized by 16S rRNA-based sequencing and a panel of 31 antimicrobial resistance genes was tested using targeted qPCR. Confirmatory shotgun metagenomic sequencing was executed on a subset of samples. The overall gut microbial community composition and antimicrobial resistance gene profile majorly shift directly following treatment (R2 = 9.5%, adjusted p-value = 0.001 and R2 = 7.5%, adjusted p-value = 0.001, respectively) and normalize over 12 months (R2 = 1.1%, adjusted p-value = 0.03 and R2 = 0.6%, adjusted p-value = 0.23, respectively). We find a decreased abundance of Bifidobacterium spp. and increased abundance of Klebsiella and Enterococcus spp. in the antibiotic treated infants compared to controls. Amoxicillin + cefotaxime shows the largest effects on both microbial community composition and antimicrobial resistance gene profile, whereas penicillin + gentamicin exhibits the least effects. These data suggest that the choice of empirical antibiotics is relevant for adverse ecological side-effects.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bactérias / Microbioma Gastrointestinal / Sepse Neonatal / Antibacterianos Tipo de estudo: Clinical_trials Limite: Humans / Newborn Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bactérias / Microbioma Gastrointestinal / Sepse Neonatal / Antibacterianos Tipo de estudo: Clinical_trials Limite: Humans / Newborn Idioma: En Ano de publicação: 2022 Tipo de documento: Article